MOTS-c Peptide

In the landmark 2015 Cell Metabolism study, Lee et al. demonstrated that MOTS-c treatment in diet-induced obese mice:

• Prevented high-fat diet-induced obesity and insulin resistance
• Reduced body weight gain by ~40% compared to controls
• Improved glucose tolerance and insulin sensitivity
• Enhanced skeletal muscle glucose uptake via GLUT4 translocation
• Reduced hepatic lipid accumulation

Importantly, circulating MOTS-c levels decline with age and correlate inversely with insulin resistance, suggesting it may be a biomarker and therapeutic target for metabolic aging.

MOTS-c has been termed an "exercise mimetic" because it activates the same AMPK-PGC1α pathway engaged by physical exercise. Research shows:

• MOTS-c treatment improves physical performance in aged mice
• Enhances skeletal muscle mitochondrial biogenesis
• Increases beta-oxidation capacity
• The peptide is released into circulation during exercise, suggesting it mediates some exercise benefits

WADA added MOTS-c to its prohibited list in 2023, recognizing its performance-enhancing potential.

MOTS-c levels decline significantly with age in humans, correlating with insulin resistance and metabolic dysfunction. A 2019 study found circulating MOTS-c was 2.5-fold lower in elderly subjects (ages 70-81) compared to young adults (20-35). Importantly, physical exercise increases MOTS-c secretion from skeletal muscle, suggesting it mediates some of the metabolic benefits of exercise.

In aged mice (24 months), MOTS-c treatment restored physical function to levels comparable to 3-month-old mice, improved glucose tolerance, and reduced body fat percentage. These anti-aging effects were dependent on AMPK activation — AMPK-knockout mice did not respond to MOTS-c.

Emerging research shows MOTS-c has cardiovascular protective effects beyond metabolic regulation. Studies demonstrate: reduced cardiac hypertrophy in pressure-overload models, protection against ischemia-reperfusion injury through AMPK-mediated autophagy, decreased inflammatory cytokine production (TNF-α, IL-6) in cardiac tissue, and improved endothelial function via eNOS upregulation. These cardioprotective effects parallel those seen with exercise training, further supporting the "exercise mimetic" classification.

A naturally occurring MOTS-c variant (K14Q, m.1382A>C) is prevalent in East Asian populations (~30% frequency) and associated with increased longevity in Japanese centenarian studies. This variant shows enhanced metabolic activity compared to wild-type, suggesting evolutionary selection for metabolic fitness. The K14Q variant provides a natural human experiment validating the MOTS-c pathway in longevity.

The landmark 2015 paper by Lee et al. in Cell Metabolism established MOTS-c as the first mitochondrial-derived peptide (MDP) with systemic metabolic regulatory function. The investigators identified a short open reading frame (sORF) within the mitochondrial 12S rRNA gene (MT-RNR1) encoding a 16-amino-acid peptide and characterized its biological activity in cell culture, rodent models, and human plasma.

Study design: C57BL/6 mice were administered MOTS-c (5 mg/kg/day, intraperitoneal) for 7-14 days while fed either standard chow or a high-fat diet (60% kcal from fat). Insulin sensitivity was assessed by glucose tolerance test (GTT) and hyperinsulinemic-euglycemic clamp. Parallel experiments used L6 myotubes and primary myocytes to dissect signaling.

Key findings:

• AMPK activation: MOTS-c increased phospho-AMPKα (Thr172) approximately 2-fold in skeletal muscle within 30 minutes of administration.
• Glucose disposal: Insulin-stimulated glucose uptake in skeletal muscle increased by ~60% in MOTS-c-treated mice on high-fat diet.
• Diet-induced obesity reversal: MOTS-c administration prevented high-fat-diet-induced weight gain and reversed established insulin resistance, reducing fasting glucose and HOMA-IR.
• Folate cycle modulation: Metabolomic profiling revealed MOTS-c targets the folate-methionine cycle, accumulating AICAR endogenously and thereby activating AMPK indirectly.
• Endogenous expression: MOTS-c was detectable in mouse plasma, skeletal muscle, and multiple tissues; circulating levels declined with age.

This study provided foundational evidence that the mitochondrial genome encodes bioactive peptides that act in retrograde fashion to coordinate nuclear and cytoplasmic metabolic responses, repositioning mitochondria as endocrine organs in addition to bioenergetic hubs.

While MOTS-c was initially characterized as a circulating metabolic regulator, work by Kim et al. (2018) in Cell Metabolism revealed a second mechanism: under metabolic stress, MOTS-c translocates from mitochondria to the nucleus, where it directly modulates nuclear gene expression — a rare example of mitochondrial-to-nuclear protein signaling.

Study design: HEK293 cells, mouse embryonic fibroblasts, and skeletal muscle tissue were exposed to glucose restriction, oxidative stress (paraquat, H₂O₂), or metformin. Subcellular fractionation, immunofluorescence, and ChIP-seq were used to track MOTS-c localization and DNA binding.

Key findings:

• Stress-induced nuclear translocation: Within 4-24 hours of metabolic stress, MOTS-c accumulated in the nucleus in an AMPK-dependent manner.
• Transcription factor co-regulation: Nuclear MOTS-c bound chromatin at antioxidant response element (ARE) sites and co-regulated transcription factors including NRF2, driving expression of stress-protective and metabolic adaptation genes.
• Functional consequence: MOTS-c knockdown impaired the cellular transcriptional response to metabolic stress, increasing reactive oxygen species and reducing viability.
• Conserved retrograde signal: The findings establish MOTS-c as a mitochondrial-encoded transcriptional regulator that integrates bioenergetic status with nuclear gene expression.

This dual cytoplasmic/nuclear mode of action distinguishes MOTS-c from canonical secreted peptide hormones and provides a mechanistic basis for its broad effects on metabolism, inflammation, and cellular resilience observed in subsequent studies.

A 2021 study by Reynolds et al. in Nature Communications directly tested whether exogenous MOTS-c could counteract age-related declines in physical performance, addressing the observation that endogenous MOTS-c levels fall with age in humans and rodents.

Study design: Young (2-month) and aged (22-month) male C57BL/6N mice received MOTS-c (5-15 mg/kg, IP) or vehicle. Outcomes included treadmill running capacity, grip strength, body composition, and skeletal muscle transcriptomics. A separate cohort underwent late-life intervention with MOTS-c + exercise training.

Key findings:

• Restored running capacity: Aged mice receiving MOTS-c ran ~2-fold longer on a treadmill at maximum effort versus vehicle-treated aged controls.
• Improved physical performance: Grip strength and gait metrics improved in MOTS-c-treated aged mice toward young-adult values.
• Healthspan extension: Late-life MOTS-c treatment beginning at 23.5 months increased measures of healthspan including activity and metabolic flexibility, even in mice already exhibiting frailty.
• Muscle transcriptome: RNA-seq showed MOTS-c reversed multiple age-associated transcriptional signatures, particularly genes involved in mitochondrial biogenesis, fatty-acid oxidation, and proteostasis.
• Human relevance: Plasma MOTS-c was significantly lower in older versus younger humans, paralleling rodent findings.

The study positions MOTS-c as a candidate geroprotector with particular promise for sarcopenia and age-related exercise intolerance research, and supports its inclusion in the broader class of mitochondrial-targeted longevity interventions.